7 results about "Respiratory allergy" patented technology

Disclosed in the present invention is a fusion protein inhalant for treating respiratory allergic diseases. The present invention provides a use of a fusion protein in preparation of a drug for treating respiratory allergic diseases. The fusion protein has an amino acid sequence as shown in SEQ ID NO: 3. The fusion protein inhalant provided by the present invention can effectively reduce inflammatory cell infiltration in lung tissue and around bronchi, and reduce airway hyperresponsiveness.

The invention discloses application of bifidobacterium animalis in relieving respiratory tract allergy symptoms, and belongs to the technical field of microorganisms. The technical problem to be solved is to provide the application of the bifidobacterium animalis in relieving the respiratory tract allergy symptoms, the key point of the technical scheme is the application of the bifidobacterium animalis subsp. Lactis BL-5M in relieving the respiratory tract allergy symptoms, and the preservation number of the bifidobacterium animalis subsp. Lactis BL-5M is CGMCC (China General Microbiological Culture Collection Center) No.33449. The medicine can act on the core mechanism of respiratory tract allergy, and the sneezing / cough frequency caused by respiratory tract stimulation reflex is reduced; the lung tissue enlargement mediated by allergic inflammation is relieved; the ratio of eosinophilic granulocytes in bronchoalveolus is reduced; the concentration of proinflammatory factors IL-4 and IL-5 in bronchoalveolus alveolus is reduced; inflammatory cell infiltration around the lung airway wall is reduced; the IgE content in a body circulation system or local tissues is reduced, meanwhile, the diversity of intestinal flora is improved, anti-inflammatory functional flora is accurately enriched, and the allergic asthma is improved in a targeted manner.

The present application relates to the use of Lactobacillus casei GKC1 for preparing an oral composition for reducing the endotoxin content in serum. After the administration of Lactobacillus casei GKC1 to a subject with respiratory allergy, the respiratory resistance of the subject is improved, and the content of immunoglobulin E specific to allergen and the content of endotoxin in the serum of the subject are reduced, so that Lactobacillus casei GKC1 can be used as an effective component of an oral composition for reducing the endotoxin content in serum.

This invention discloses a method for manufacturing a negative ion device for preventing and treating airborne viral infections. Specifically, water is added to tourmaline pebbles to moisten them, but not completely immerse them, and additional air pressure is applied to the surface of the wet tourmaline pebbles. The pressure of the tourmaline is used to generate a pressure-electric electrode that is far greater than the spontaneous polarization effect, ionizing surrounding water molecules to produce a large number of hydroxide and hydrogen ions. Hydrogen ions have a weaker electron-capturing ability compared to oxygen molecules and are the lightest substance, so they disperse immediately after being blown out by the fan, resulting in a very low content in the environment. After the hydroxide ions donate electrons, water and oxygen are produced, and the electrons that donate them combine with oxygen molecules blown in by the fan and oxygen molecules produced by their own reactions to form intrinsic negative ions by Brownian motion. Using these negative ions obtained through the Green method, it is possible to promote the decomposition of VOCs, condense and settle PM2.5, aerosols, bacteria, viruses, pollen, etc., inhibit or kill bacteria, change or reverse the polarity of the potential inside and outside the viral capsid, break down the viral spike, rapidly inactivate viruses, and prevent viruses from entering human cells by blocking electrostatic attraction between the viral receptor binding region and the cell membrane receptor. At the same time, it has other health and therapeutic effects such as alleviating respiratory allergies, improving respiratory and circulatory functions, aiding sleep, preventing fatigue, antioxidant, removing free radicals in the body, increasing the body's repair capacity, and enhancing immunity. It can also generate and replenish diffused oxygen and perform mist-free humidification.

Disclosed in the present invention is a fusion protein inhalant for treating respiratory allergic diseases. The present invention provides a use of a fusion protein in preparation of a drug for treating respiratory allergic diseases. The fusion protein has an amino acid sequence as shown in SEQ ID NO: 3. The fusion protein inhalant provided by the present invention can effectively reduce inflammatory cell infiltration in lung tissue and around bronchi, and reduce airway hyperresponsiveness.

The application discloses an animal bifidobacterium lactis strain capable of producing indole-3-carboxaldehyde to relieve respiratory allergic diseases caused by ovalbumin, and belongs to the technical field of microorganisms and the technical field of medicine. The application provides an animal bifidobacterium lactis strain CCFM1274 capable of relieving the pathological characteristics of asthma mice and further relieving asthma. After the animal bifidobacterium lactis strain CCFM1274 is used on the asthma mice, allergic symptoms of the mice can be significantly relieved. Therefore, the animal bifidobacterium lactis strain CCFM1274 has great application prospect in the preparation of products for preventing and / or treating respiratory allergic diseases such as asthma.

The application relates to an antigen epitope peptide derived from a dust mite allergen and application thereof, and belongs to the technical field of immune detection. The antigen epitope peptide derived from allergens Der p 23 and Der f 23 is screened for the first time, the antigen epitope peptide can effectively capture IgE in serum samples of patients with respiratory allergic diseases, the positive rate of the captured IgE has no significant difference with the capture ability of complete allergens, and the antigen epitope peptide has wide application value in the diagnosis of respiratory allergic diseases. In addition, the antigen epitope peptide can induce cells to produce thymic stromal lymphopoietin (TSLP), interleukin-33 (IL-33) and interleukin-25 (IL-25), and then start and amplify the 2-type immune response, so that the antigen epitope peptide has a good application prospect in the preparation of vaccines for dust mite allergy.